

October 5, 1965

Dr. Vincent Y. Cremata, Jr.
Associate Director of Clinical Research
Chas. Pfizer & Co., Inc.
Department of Clinical Research
Medical Research Laboratories
Groton, Connecticut

Dear Dr. Cremata:

I want to take this opportunity to thank you for inviting me to participate in the review of P-4657B. As I expressed in that meeting, I believe that the data presented clearly demonstrates that thiothixene has potent antipsychotic activity and that its continued study is to be recommended.

At the next meeting of the Pharmacological Committee of this Center, I will present a summary of these observations. As soon as the workload in my own service permits, I would like to undertake a study of this compound and will call you.

As I suggested at the end of the meeting, I am in the process of reviewing some of the newer anticholinergic compounds which may have application in the treatment of depressives, for presentation at a symposium at an international meeting in March.

I would be interested in reviewing the pharmacological data which led to the recommendation of trials in depressive subjects.

May I take this opportunity again to thank you and your associates for your kind invitation.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp